Symbiotec Pharmalab Share Price Surges 20%; Signs Protein Manufacturing Deal with European Firm

Symbiotec Pharmalab Limited has signed a 10-year contract with a European alternative protein company to manufacture proteins using fermentation technology. The agreement was announced on November 6, 2026, through a regulatory filing. 

The contract is based on a take-or-pay arrangement, under which the European company will have dedicated manufacturing capacity reserved at Symbiotec's facility for the duration of the agreement.  

The financial details of the contract have not been disclosed due to confidentiality obligations. 

Production at Madhya Pradesh Facility 

Manufacturing will begin at Symbiotec's biomanufacturing campus in Ujjain, Madhya Pradesh. The existing facility has four fermenters, each with a capacity of 100 kilolitres (kL), along with downstream processing equipment and quality assurance and quality control facilities. 

The company plans to set up another dedicated plant with fermentation capacity of several hundred thousand litres. The agreement also includes options for further expansion, with the programme's total capacity potentially reaching millions of litres. 

Production will initially take place at the existing facility before shifting to the expanded manufacturing infrastructure. 

Alternative Protein Manufacturing 

The agreement covers precision fermentation, a process that uses engineered microorganisms to produce proteins traditionally obtained from animals. These proteins are used in the development of alternative food ingredients. 

Symbiotec will undertake the manufacturing using its existing fermentation infrastructure and pharmaceutical quality systems. The company also has experience in setting up and operating fermentation plants. 

Managing Director Anil Satwani said the agreement covers opportunities in alternative proteins, human nutrition and industrial bioproducts. 

Symbiotec Pharmalab Operations 

Founded in 1995, Symbiotec Pharmalab operates in pharmaceuticals and biotechnology. Its business includes active pharmaceutical ingredients (APIs), contract development and manufacturing organisation (CDMO) services, and complex injectables. 

The company has more than 200 customers across over 40 countries and operates four manufacturing facilities in Madhya Pradesh. Its facilities hold USFDA, EU-GMP, WHO-GMP and Japan-PMDA approvals. 

Read More: Gokaldas Exports Share Price Drops Over 10% After Q2FY27 Results! 

Symbiotec Pharmalab Share Price Performance 

As of November 6, 2026, 3:28 pm, Symbiotec Pharmalab Ltd share price was trading at ₹1,525.80, up 20.00% from the previous closing price. 

Conclusion 

The agreement covers an initial manufacturing arrangement at Ujjain, followed by additional plant capacity and further expansion options. The contract period is 10 years. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.